Use of paclitaxel cationic liposome in treating tumors

(canceled)

A method for treating advanced solid tumors, wherein a therapeutically effective amount of a paclitaxel cationic liposome is administered to a patient with advanced solid tumors.

A method for treating advanced solid tumors, wherein a therapeutically effective amount of a paclitaxel cationic liposome and a systemic therapeutic drug are administered to a patient with advanced solid tumors, optionally, a therapeutically effective amount of the paclitaxel cationic liposome, capecitabine, and oxaliplatin are administered to the patient with the advanced solid tumors, the paclitaxel cationic liposome is administered via arterial infusion.

A method for improving the efficacy of a systemic therapeutic drug on tumors, wherein a therapeutically effective amount of a paclitaxel cationic liposome is further administered to a patient in addition to the systemic therapeutic drug, the systemic therapeutic drug is capecitabine and oxaliplatin, or cisplatin, or gemcitabine, or capecitabine.

A method for improving the efficacy of a combination of capecitabine and oxaliplatin on advanced solid tumors including advanced gastric cancer, colorectal cancer, and pancreatic cancer, wherein a therapeutically effective amount of a paclitaxel cationic liposome is further administered to a patient in addition to capecitabine and oxaliplatin.